← Evidence map

ArticleBiomedicines2026

Preliminary Effects of Benralizumab in an AML Cell Model with Promyelocytic Features Expressing IL-5R: An Exploratory Proof-of-Concept Study.

Giovanna Lucia Piazzetta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Preliminary Effects of Benralizumab in an AML Cell Model with Promyelocytic Features Expressing IL-5R: An Exploratory Proof-of-Concept Study. | OpenQuestion